Search

Myelin oligodendrocyte glycoprotein-associated disease (MOGAD) is an inflammatory neurological disease. It progresses with attacks by affecting the optic nerves and spinal cord. Bilateral or recurrent optic neuritis are the most common findings in adult patients. Its association with systemic autoimmune disorders such as Sjögren syndrome, antiphospholipid syndrome, autoimmune thyroiditis, and celiac disease is rare. The first and only case of MOGAD in a patient with ankylosing spondylitis with a history of anti-tumor necrosis factor-alpha (anti-TNF-α) use was reported. Herein, we present the coexistence of MOGAD in a patient with AS who did not have a history of anti-TNF-α therapy. [ABSTRACT FROM AUTHOR]

Copyright of Sakarya Tıp Dergisi is the property of Sakarya Tip Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Sakarya Tıp Dergisi is the property of Sakarya Tip Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Amaç: Geriatrik yaş grubundaki romatoid artrit (RA) ve psoriatik artrit (PsA) hastalarında konvansiyonel DMARD sonrası ilk tercih edilen biyolojik veya hedefe yönelik sentetik hastalık modifiye edici antiromatizmal ilaçlar (bDMARD'lar ve tsDMARD'lar) iyi çalışılmamıştır. Bu çalışmada, romatoid artrit ve psoriatik artritli geriatrik ve genç erişkin popülasyonda konvansiyonel DMARD sonrası ilk tercih edilen bDMARD veya tsDMARD'lar arasındaki farklılıkların ve ilaçta kalımın araştırılması hedeflenmiştir. Yöntem: TReasure, 2017 yılında oluşturulan Türkiye'nin farklı bölgelerindeki 17 romatoloji merkezi tarafından RA ve spondiloartrit (SpA) hastalarından veri toplamak için oluşturulan web tabanlı, çok merkezli bir veri tabanıdır. Bu çalışmada TReasure veri tabanından toplanan RA'lı 3136 ve PsA'lı 738 hasta değerlendirmeye alınmıştır. İlk tercih edilen bDMARD veya tsDMARD, tanımlayıcı istatistiksel yöntemle, ilaçta kalım Kaplan-Meier yöntemi ile değerlendirilmiştir. Bulgular: RA'lı hastaların %12'si geriatrik popülasyondaydı. Altmış beş yaş altındaki RA'lı hastalarda konvansiyonel DMARD sonrası romatoloji uzmanları tarafından ilk tercih edilen bDMARD/tsDMARD'lara bakıldığında, sırasıyla adalimumab (%20,6), etanersept (%19,9) ve tofasitinib (%13,6) olduğu gözlenirken, ≥65 yaşta sırasıyla rituksimab (%24), tofasitinib (%20,9) ve etanersept (%13) tercih edilmiştir. PsA hastalarının %3'ü 65 yaş ve üzerindeydi. Altmış beş yaş altındaki PsA hastalarında konvansiyonel DMARD sonrası ilk başlanan ilaçlar sırasıyla adalimumab (%41,1), etanersept (%17,6) ve infliksimab (%15,5); ≥65 yaşta ise sırasıyla adalimumab (%28,6), etanersept (%17,9) ve sertolizumab (%17,9) olduğu gözlenmiştir. RA grubunda, 65 yaş ve üzeri hastalarda; PsA grubunda ise 65 yaş altı hastalarda ilaçta kalım daha uzun olarak saptanmıştır. Sonuç: Hastanın yaşının hekimin ilk bDMARD/tsDMARD seçimini etkileyebildiği görülmüştür. Altmış beş yaş altı RA hastalarında ilk anti-TNFα ilaçlar tercih edilirken 65 yaş ve üstü hastalarda ilk sırada rituksimab ve tofasitinib tercih edilmiştir. PsA'lı hem yaşlı hem de genç hastalarda ilk olarak anti-TNFα tercih edilmiştir. Rituksimab ve tofasitinibin PsA da kullanımının sınırlı olduğu göz önüne alınmalıdır. İlacın uygulanım şekillerinin (rituksimabın uzun aralıklarla hastane kontrolünde, tofasitinibin oral kullanımı) geriatrik popülasyonda romatologların ilaç seçimini etkileyebileceği sonucuna varılmıştır. [ABSTRACT FROM AUTHOR]

Objectives: This study aims to determine femoral cartilage thickness using ultrasonography in familial Mediterranean fever (FMF). Patients and methods: A total of 45 patients (16 males, 29 females; mean age: 38.5±9.1 years; range, 24 to 49 years) with the diagnosis of FMF and 31 healthy individuals (6 males, 25 females; mean age: 37.0±8.7 years; range, 25 to 47 years) between January 2016 and July 2016 were included in this study. Clinical data and demographic characteristics of the patients were recorded. All FMF cases in the study were in remission with colchicine treatment. The thickness of femoral cartilage in both knees were evaluated using ultrasonography. Three measurements (mid-point) were taken from both knees (at the medial/lateral femoral condyles and intercondylar area). Results: Ultrasonographical measurements revealed that cartilage measurements of FMF patients were significantly thinner at both the medial/lateral femoral condyles and intercondylar area on the right knee and at the medial/lateral femoral condyles on the left knee (p<0.001). The cartilage measurements in FMF patients were significantly thinner at the intercondylar area on left knee, compared to those in controls (p=0.023). Conclusion: Our study showed decreased femoral cartilage thickness in FMF patients. These findings indicate that even if these patients do not have an attack, they may have subacute and chronic arthritis in their joints, and their femoral cartilage thickness can be affected. [ABSTRACT FROM AUTHOR]

Objectives Our aim is to understand clinical characteristics, real-life treatment strategies, outcomes of early PsA patients and determine the differences between the inception and established PsA cohorts. Methods PsArt-ID (Psoriatic Arthritis- International Database) is a multicentre registry. From that registry, patients with a diagnosis of PsA up to 6 months were classified as the inception cohort (n ==388). Two periods were identified for the established cohort: Patients with PsA diagnosis within 5–10 years (n  = 328), ≥10 years (n  = 326). Demographic, clinical characteristics, treatment strategies, outcomes were determined for the inception cohort and compared with the established cohorts. Results The mean (s. d.) age of the inception cohort was 44.7 (13.3) and 167/388 (43.0%) of the patients were male. Polyarticular and mono-oligoarticular presentations were comparable in the inception and established cohorts. Axial involvement rate was higher in the cohort of patients with PsA ≥10 years compared with the inception cohort (34.8% vs 27.7%). As well as dactylitis and nail involvement (P = 0.004, P = 0.001 respectively). Both enthesitis, deformity rates were lower in the inception cohort. Overall, 13% of patients in the inception group had a deformity. MTX was the most commonly prescribed treatment for all cohorts with 10.7% of the early PsA patients were given anti-TNF agents after 16 months. Conclusion The real-life experience in PsA patients showed no significant differences in the disease pattern rates except for the axial involvement. The dactylitis, nail involvement rates had increased significantly after 10 years from the diagnosis and the enthesitis, deformity had an increasing trend over time. [ABSTRACT FROM AUTHOR]

Objective: Cardiac involvement is seen in 10-30% of patients with ankylosing spondylitis (AS). Chronic inflammation plays major rol for patophysiology of AS as well as cardiovascular disease, hypertension anddiurnal blood pressure variability (DBPV). Decreased DBPVis a marker of high risk for cardiovascular events. Our aim is to compare DBPV in AS patients with normal population. Material and Methods: A total of 25 AS patients and 32 controls enrolled for this study. Hypertensive patients were defined according to results of ambulatory blood pressure monitorization (ABPM) results or patients under hypertensive treatment. Dipper status was defined as %10 or more systolic blood pressure (BP) fall compared to daytime values. Results: The mean age of study population was 42.5±12.1 years and 63.2% were male. There was no significant difference between control group and AS group in terms of basic demographics. According to ABPM results; 36% (n=9) of the AS group and 46.9% (n=15) of the control group were hypertensive and there was no statistical difference between groups (p=0.290). Mean, daytime and nighttime sistolic and diastolic BP were similar (p>0.05). Non-dipper pattern was found in 76.0% (n=19) of AS patients and 71.8% (n=23) of control group. The difference between these ratios was not statistically significant (p=0.949). There was no difference between the groups in terms of DBPV(p=0.772). Conclusion: In conclusion, non-dipper pattern and DBPV were similar in AS patients and control group. When assessed by subgroup analysis of hypertensive and normotensive patients, there was no difference between the groups in terms of non-dipper patients and DBPV. [ABSTRACT FROM AUTHOR]

Background/aim: The distribution of Mediterranean fever (MEFV) gene mutations in Turkish familial Mediterranean fever (FMF) patients varies according to geographic area of Turkey. There is a need for highly representative data for Turkish FMF patients. The aim of our study was to investigate the distribution of the common MEFV mutations in Turkish FMF patients in a nationwide, multicenter study. Materials and methods: Data of the 2246 FMF patients, from 15 adult rheumatology clinics located in different parts of the country, were evaluated retrospectively. The following mutations have been tested in all patients: M694V, M680I, M694I, V726A, and E148Q. Results: There were 1719 FMF patients with available genetic testing. According to the genotyping, homozygous M694V, present in 413 patients (24%), was the most common mutation. One hundred and fifty-four (9%) of patients had no detectable mutations. Allele frequencies of common mutations were: M694V (n = 1529, 44.5%), M680I (n = 423, 12.3%), V726A (n = 315, 9.2%), E148Q (n = 214, 1%), and M694I (n = 12, <1%). Conclusion: In this large-scale multicenter study, we provided information about the frequencies of common MEFV gene mutations obtained from adult Turkish FMF patients. Nearly half of the patients were carrying at least one M694V mutations in their alleles. [ABSTRACT FROM AUTHOR]

Objective: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Most of the identified disease-causing mutations are located on exon 10. As the number of studies about the effect of the exonal location of the mutation and its phenotypic expression is limited, we aimed to investigate whether the exonic location of the Mediterranean fever (MEFV) mutation has an effect on the clinical manifestation in patients with FMF. Methods: Study population was derived from the main FMF registry that included 2246 patients from 15 different rheumatology clinics. We categorized the mutations according to their exon locations and retrieved the clinical and demographic information from the database. Results: Patients having the MEFV mutations on exon 2 or 10 (n:1526) were divided into three subgroups according to the location of the MEFV mutations: Group 1 (exon 2 mutations), Group 2 (exon 10 mutations), and Group 3 (both exon 2 and exon 10 mutations). Group 2 patients were of a significantly younger age at onset, and erysipel-like erythema, arthritis, amyloidosis, and a family history of FMF were more common in this group. Conclusion: Patients with FMF and exon 10 mutations show more severe clinical symptoms and outcome. Exon 2 mutations tend to have a better outcome. [ABSTRACT FROM AUTHOR]